Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Phase 1

Evaluation of Bone Behavior in Maxillary Post-extractive Sites Treated With Guided Bone Regeneration (G.B.R.) Techniques in Alveolar Socket Preservation (A.S.P.) Procedures With Different Autologous and Heterologous Biomaterials.

NCT07269990 · tracked via the Priya Life Science Italy tracker
Phase
Phase 1
Started
2023-07-03
Last updated
2026-04-30

Condition(s) studied

Extracting Own Teeth

Investigational drug(s) / intervention(s)

compare different types of biomaterials 4 months after application through the use of ASP compare different types of biomaterials 4 months after application through the use of ASP Group 2Comparison of different types of biomaterials 4 months after application through the use of ASPComparison different types of biomaterials 4 months after application through the use of ASPThe aim is to compare different types of biomaterials 4 months after application through the use of ASPThe aim is to compare different types of biomaterials 4 months after application through the use of ASP

compare different types of biomaterials 4 months after application through the use of ASP compare different types of biomaterials 4 months after application through the use of ASP Group 2: The aim is to compare different types of biomaterials 4 months after application through the use of ASP in Group 1

Comparison of different types of biomaterials 4 months after application through the use of ASP: The aim is to compare different types of biomaterials 4 months after application through the use of ASP in Group 2

Comparison different types of biomaterials 4 months after application through the use of ASP: The aim is to compare different types of biomaterials 4 months after application through the use of ASP in Group 3

The aim is to compare different types of biomaterials 4 months after application through the use of ASP: The aim is to compare different types of biomaterials 4 months after application through the use of ASP in Group 4

The aim is to compare different types of biomaterials 4 months after application through the use of ASP: The aim is to compare different types of biomaterials 4 months after application through the use of ASP in Group 5

Study summary

The maxillary bone atrophies from traumatic, pathological events or related to physiological bone loss after tooth extraction, promoting a decrease in bone volume (vertical-horizontal) which has always been a crucial challenge for the clinician in order to obtain adequate rehabilitations prosthetics.

The results of bone loss induced aesthetic and functional difficulties in achieving surgical and prosthetic rehabilitation of the right dental implant.

Bone loss can be restored with autologous bone grafts and in large bone atrophy of the jaws require complex surgical techniques such as vascularized bone transplantation.

As an alternative to the reconstruction of the maxillary tissue, several surgical techniques have been promoted to prevent or minimize bone resorption through market biomaterials with or without the patient's autologous bone.

To reduce or counteract biological bone resorption, surgeons have promoted alveolar cavity preservation procedures (ASP) with autologous or heterologous graft materials.

Recently, several studies have been published to evaluate the use of demineralized dentin material derived from the extracted tooth to obtain new bone in the maxillary post-extraction site.

The aim of the study is to compare different types of biomaterials 4 months after application through the use of the alveolar socket preservation technique.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy patients. * Diagnosis of tooth extraction in the upper or lower jaw. * Preservation procedures necessary to preserve jawbone volume with Guided * Bone regeneration with autologous or heterologous biomaterials. Exclusion Criteria: * Patients with high risk of receiving the intervention (pre-existing medical conditions/comorbidities/possible adverse events). * Patients with conditions that may interfere with the evaluation or confound the results. (e.g. they are already taking treatments) * Patients with refusal to participate, inability to provide data, or at high risk of loss to follow-up. * Patients with neoplastic pathologies. * Patients with Radio-Chemo therapies.

Primary outcome measure(s)

  • Comparison of different biomaterials at 4 months to assess the percentage of residual biomaterial remaining in situ and the percentage of newly formed bone in the regenerated area. — 4 months after surgery

Trial sites (1)

FacilityCityRegionStatus
University of Foggia Foggia Foggia
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07269990 on ClinicalTrials.gov ↗ ← All trials in Italy